Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTAP101 for Secondary Hyperparathyroidism in Pediatric CKD
NCT05543928Phase 3Terminated
- Sponsor
- OPKO Health
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) and Vitamin D deficiency (VDD) comparing Placebo with CTAP101 (2 arms). Primary endpoints: Numbers of Subjects Who Attained Mean Decrease in Plasma iPTH of 30% From Baseline at 26 weeks, Safety and Tolerability at 26 weeks and 1 more. Started Jan 2023; status: terminated.
02
Drugs
calcifediol
03
Conditions
secondary hyperparathyroidism (SHPT)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on NCT05543928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543928.